M. Mariani

Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study

S. Severi, D. Metz, J. Berlin, 2020, European Journal of Nuclear Medicine and Molecular Imaging.

177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial.

E. Mittra, E. Van Cutsem, James C Yao, 2021, The Lancet. Oncology.

MITIGATE-NeoBOMB1, a Phase I/IIa Study to Evaluate Safety, Pharmacokinetics, and Preliminary Imaging of 68Ga-NeoBOMB1, a Gastrin-Releasing Peptide Receptor Antagonist, in GIST Patients

S. Schoenberg, G. Glatting, P. Hohenberger, 2020, The Journal of Nuclear Medicine.

Therapeutic efficacy of 166Holmium siloxane in microbrachytherapy of induced glioblastoma in minipig tumor model

O. Tillement, L. Marcon, F. Haddad, 2022, Frontiers in Oncology.

Imaging Properties and Tumor Targeting of 68Ga-NeoBOMB1, a Gastrin-Releasing Peptide Receptor Antagonist, in GIST Patients

H. Tilg, P. Hohenberger, W. Jaschke, 2022, Biomedicines.